Silo Pharma Valuation
| SILO Stock | USD 0.88 0.01 1.15% |
Today, the company appears to be overvalued. Silo Pharma has a current Real Value of $0.83 per share. The regular price of the company is $0.88. Our model measures the value of Silo Pharma from inspecting the company fundamentals such as Return On Equity of -0.44, current valuation of (2.06 M), and Shares Owned By Insiders of 6.34 % as well as reviewing its technical indicators and probability of bankruptcy. . In general, most investors recommend obtaining undervalued stocks and abandoning overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Overvalued
Today
Please note that Silo Pharma's price fluctuation is abnormally volatile at this time. Calculation of the real value of Silo Pharma is based on 3 months time horizon. Increasing Silo Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Silo otc stock is determined by what a typical buyer is willing to pay for full or partial control of Silo Pharma. Since Silo Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Silo OTC Stock. However, Silo Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.88 | Real 0.83 | Hype 0.88 |
The intrinsic value of Silo Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Silo Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Silo Pharma helps investors to forecast how Silo otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Silo Pharma more accurately as focusing exclusively on Silo Pharma's fundamentals will not take into account other important factors: Silo Pharma Total Value Analysis
Silo Pharma is at this time expected to have valuation of (2.06 M) with market capitalization of 5.6 M, debt of , and cash on hands of 8.85 M. The negative valuation of Silo Pharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Silo Pharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(2.06 M) | 5.6 M | 8.85 M |
Silo Pharma Investor Information
The company has price-to-book ratio of 0.93. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Silo Pharma has Price/Earnings (P/E) ratio of 118.39. The entity recorded a loss per share of 1.18. The firm had not issued any dividends in recent years. Silo Pharma had 1:50 split on the 15th of September 2022. Based on the key measurements obtained from Silo Pharma's financial statements, Silo Pharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Silo Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Silo Pharma has an asset utilization ratio of 0.93 percent. This suggests that the OTC Stock is making $0.009308 for each dollar of assets. An increasing asset utilization means that Silo Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Silo Pharma Ownership Allocation
Silo Pharma has 6.35 % of its outstanding shares held by insiders and 5.6 % owned by institutional holders.Silo Pharma Profitability Analysis
The company reported the previous year's revenue of 72.1 K. Net Loss for the year was (3.63 M) with profit before overhead, payroll, taxes, and interest of 66.26 K.About Silo Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Silo Pharma. In general, an absolute valuation paradigm, as applied to this otc stock, attempts to find the value of Silo Pharma based exclusively on its fundamental and basic technical indicators. By analyzing Silo Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Silo Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Silo Pharma. We calculate exposure to Silo Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Silo Pharma's related companies.Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.
8 Steps to conduct Silo Pharma's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Silo Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Silo Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Silo Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Silo Pharma's revenue streams: Identify Silo Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Silo Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Silo Pharma's growth potential: Evaluate Silo Pharma's management, business model, and growth potential.
- Determine Silo Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Silo Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Silo Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 3.1 M |
Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.